The utility of adrenaline beta3 receptor agonist as a new drug for Parkinson's disease
| Project/Area Number |
25870943
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Pharmacology in pharmacy
General pharmacology
|
|---|
| Research Institution | Setsunan University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2015: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | パーキンソン病 / β3受容体作用薬 / 神経保護作用 / β3受容体アゴニスト / グルタチオン / アストロサイト / パーキンソン病モデル / ドパミン神経細胞 / ドパミン神経細胞保護 / 細胞内シグナル伝達系 |
|---|
| Outline of Final Research Achievements |
I investigated that adrenaline β3 receptor agonist could be a new drug for Parkinson's disease using MPTP-induced mouse Parkison's disease model. β3 receptor agonist increased glutathione levels in mouse brain and inhibited MPTP-induced death of dorpaminergic neurons.
|
Report
(4 results)
Research Products
(8 results)
